CRTCampaign for Responsible Transplantation  action alertscontact CRT
About CRT
What is Wrong With Xeno?
Alternatives to Xenotransplantation
Who is Developing Xeno?
Press Releases
Publications and Resources
Xeno Humor

Animal Transplants: Not the Cure for the Organ Shortage

March 2, 1999
Providence (RI) Journal-Bulletin

Americans for Medical Progress (AMP), a public relations front for the animal research industry, has launched an irresponsible campaign to promote animal organ and tissue transplants (xenotransplants), using the plight of liver transplant patients like football star Walter Payton to advance its agenda. AMP's board of directors includes Leon Hirsch, AMP founder and President of US Surgical Corp., which recently sold its xenotransplantation program to Alexion Pharmaceuticals. Also represented on AMP's board is Pfizer Pharmaceuticals, a platinum sponsor of World Pork Expo, and national pig breeding programs. (Several companies in the US are breeding colonies of pigs with human genes for xenotransplants). AMP is hardly an objective source for information on xenotransplantation, and Americans should not be fooled by the group's tactics.  Xenotransplantation is not the solution to the alleged organ shortage.

In the journal Nature (5 March 1998, pp.11-12), transplant surgeon Abdullah Daar writes that "xenotransplantation will have no immediate effect on overall transplant numbers," because the technology is still highly experimental. It faces many obstacles including hyperacute rejection, retroviral infections, transfer of prions, and severe side-effects of immunosuppressive drugs. Moreover, animal and human organs differ in their anatomy, production of hormones, secretion and absorption of enzymes and other chemicals, in their resistance to disease, and longevity. In 1998, xenotransplant researcher Thomas Starzl wrote that "the prospect of successful transplantation of animal organs into humans is still remote." But the public is not holding its breath. A review of eight studies of attitudes to xenotransplantation by P.J. Mohacsi, published in the Annals of Transplantation (1998, Vol.3 No.2: 38-45) did not reveal overwhelming support for the technology. And on 29 January 1999, the Council of Europe, a barometer of public opinion for its 40 member countries, voted for a world-wide ban on the technology.

In stating that xenotransplantation of animal cells, tissues, and organs will yield effective treatments for human diseases, AMP exaggerates the technology's alleged benefits while ignoring its risks. M. M. Swindle at Medical University of South Carolina, Charleston concedes that, screening individual animals thoroughly for viruses, bacteria, fungi, and parasites in a timely fashion prior to xenotransplants would be impossible, leaving patients, care-givers, and people at large vulnerable to infections. New viruses may go undetected, and microbiological assays may be unavailable to screen for them.
US public health agencies acknowledge that xenotransplantation is unsafe, and dozens of scientific papers have elucidated the risks of xenotransplantation in great detail.  Some have pointed out that, like the AIDS crisis, the spread of a new zoonotic virus could have the undesired effect of shrinking the pool of eligible blood and organ donors. Scientists from the Food and Drug Administration's Center for Biologics Evaluation and Research have stated that "transplantation of non-human live cells presents a risk of introducing novel pathogens into the human population."
The use of "bioartificial livers," coated with pig cells to filter the blood of acutely ill patients awaiting human livers, does not increase the overall number of organs available for transplant.  Moreover, such devices do not prevent pig viruses from being transmitted to humans. Experiments using pig cells to treat diabetes, epilepsy, Huntington's and Parkinson's disease patients have not provided the long-term benefits proponents hoped for. Studies with pig cells for Parkinson's disease have raised ethical questions, as patients in control groups had holes drilled through their skulls but received no treatment.  And studies in which cancer patients were injected with calf adrenal cells to treat pain were not double-blinded.  So the temporary relief these patients experienced could be attributed to a placebo effect. AMP states that people have used pig heart valves and animal insulin for decades, and have benefited from polio vaccines made from monkey kidney cells.  But pig heart valves are soaked in glutaraldehyde before use and are biologically inert. Synthetic valves, which last longer, are replacing pig valves. Insulin (now produced synthetically, thereby reducing the risk of allergies and prion diseases) is a purified compound, not a living preparation.  And scientific studies have linked rare human brain, lung, and bone cancers to polio vaccine contaminated with simian virus 40. There are alternatives to xenotransplantation. The Boston-based Campaign for Responsible Transplantation (CRT) publicized an April 1998 General Accounting Office report on organ donation that identified a potential US organ donor pool of 150,000 people - more than double the number needed to alleviate the alleged shortage. The alleged organ shortage is merely a failure to turn potential into actual donors. Spain implemented a 'presumed consent law' and has one of the highest organ donor rates in the world. In December 1998, CRT filed a legal petition with the Department of Health and Human Services, signed by 55 scientists, physicians, veterinarians, and concerned laypersons, demanding a ban on xenotransplants.  Fueling the demand for organ transplants is unsustainable and expensive. Aggressive investment in population-based prevention and rehabilitation programs could reduce the need for transplants of all kinds. In the meantime, HHS and the medical community could do a lot more to increase human organ donation rates.

Alix Fano, MA, Director
Campaign for Responsible Transplantation
PO Box 2751
New York, NY 10163-2751
Tel. (212) 579-3477

CRT, an international coalition of 70 organizations representing over 2 million people, was launched on January 20, 1998 out of concern over the rush to commercialize xenotransplantation.